Upadacitinib for Refractory Behcet's Syndrome
- Sponsor
- Liu Tian
- Study ID
- NCT07080346
- Phase
- PHASE2
- Status
- Completed
Conditions
- Behcet Syndrome
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Upadacitinib 15 MG — DRUGAll the BS patients discontinued other biologic agents and received oral upadacitinib treatment at a dose of 15mg per day with background glucocorticoids and immunosuppressants for 48 weeks. All the patients will be followed up prospectively for 48 weeks.
Study Details
Behçet's syndrome (BS) is a systemic autoimmune vasculitis that can affect multiple organs, including the skin, eyes, and vascular system. Refractory BS poses significant treatment challenges, necessitating novel therapeutic approaches. Upadacitinib, a selective JAK1 inhibitor within the JAK-STAT pathway, has shown promise in modulating immune responses. This study aims to evaluate the efficacy and safety of upadacitinib in patients with refractory BS.
Key Dates
- Start date
- Jan 25, 2024
- Status verified
- Jul 2025
- Primary completion
- Dec 20, 2024
- Completion
- Jul 8, 2025
Study Design
- Enrollment
- 27 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treated with upadacitinibRefractory BS patients were treated with upadacitinib.
Primary Outcome Measure
Patients getting improved condition [ Time Frame: Week 24 ]